Clinical observation of nivolumab combined with cabozantinib in the treatment of advanced hepatocellular carcinoma  

作　　者：Lu-Wen Liang Rong-Hong Luo Zhi-Li Huang Li-Na Tang 

机构地区：[1]Infection and Liver Disease Center,The Second Affiliated Hospital of Chongqing Medical University,Chongqing 400000,China [2]Department of Infectious Diseases,The Third Affiliated Hospital of Chongqing Medical University,Chongqing 401120,China

出　　处：《World Journal of Gastrointestinal Oncology》2025年第4期201-209,共9页世界胃肠肿瘤学杂志(英文)

摘　　要：BACKGROUND Hepatocellular carcinoma(HCC)is a particularly serious kind of liver cancer.Liver cancer ranks third in terms of mortality rate worldwide,putting it among the leading causes of deaths from cancer.HCC is the primary kind of liver cancer and makes up the vast majority of cases,accounting for approximately 90%of occurrences.Numerous research have verified this information.the progress of fatty liver,alcohol induced cirrhosis,smoking habits,obesity caused by overweight,and metabolic diseases such as diabetes.The treatment strategies for HCC can be divided into two categories:One is curative treatment,including liver transplantation,surgical resection,and ablation therapy or selective arterial radiation embolization,aimed at completely eliminating the lesion;Another type is non curative treatment options,including transarterial chemoembolization and systemic therapy,which focus on controlling disease progression and prolonging patient survival.The majority of HCC patients are found to be in an advanced stage and need systemic therapy.Sorafenib and lenvatinib are frequently used as first-line medications in traditional HCC treatment to slow the disease's progression.For second-line treatment,regorafenib,cabozantinib,or remdesizumab are used to inhibit tumors through different mechanisms and prolong survival.In recent years,with the in-depth exploration of the pathogenesis and progression mechanism of HCC,as well as the rapid progress within the domain of tumor immunotherapy,the treatment prospects for advanced HCC patients have shown a positive transformation.This transformation is reflected in the fact that more and more patients are gradually gaining significant and considerable therapeutic advantages from advanced immunotherapy regimens,bringing unprecedented improvements to their treatment outcomes.In order to enable activated T cells to attack tumor cells,immune checkpoint inhibitors interfere with the inhibitory.AIM To evaluate the effects of nivolumab in combination with cabozantinib on patient tumor

关 键 词：Nivolumab Cabozantinib Hepatocellular carcinoma Tumor markers Immune function 

分 类 号：R73[医药卫生—肿瘤]